Your browser doesn't support javascript.
loading
A microRNA signature that correlates with cognition and is a target against cognitive decline.
Islam, Md Rezaul; Kaurani, Lalit; Berulava, Tea; Heilbronner, Urs; Budde, Monika; Centeno, Tonatiuh Pena; Elerdashvili, Vakthang; Zafieriou, Maria-Patapia; Benito, Eva; Sertel, Sinem M; Goldberg, Maria; Senner, Fanny; Kalman, Janos L; Burkhardt, Susanne; Oepen, Anne Sophie; Sakib, Mohammad Sadman; Kerimoglu, Cemil; Wirths, Oliver; Bickeböller, Heike; Bartels, Claudia; Brosseron, Frederic; Buerger, Katharina; Cosma, Nicoleta-Carmen; Fliessbach, Klaus; Heneka, Michael T; Janowitz, Daniel; Kilimann, Ingo; Kleinedam, Luca; Laske, Christoph; Metzger, Coraline D; Munk, Matthias H; Perneczky, Robert; Peters, Oliver; Priller, Josef; Rauchmann, Boris S; Roy, Nina; Schneider, Anja; Spottke, Annika; Spruth, Eike J; Teipel, Stefan; Tscheuschler, Maike; Wagner, Michael; Wiltfang, Jens; Düzel, Emrah; Jessen, Frank; Rizzoli, Silvio O; Zimmermann, Wolfram-Hubertus; Schulze, Thomas G; Falkai, Peter; Sananbenesi, Farahnaz.
Afiliação
  • Islam MR; Department for Epigenetics and Systems Medicine in Neurodegenerative Diseases, German Center for Neurodegenerative Diseases, Göttingen, Germany.
  • Kaurani L; Department for Epigenetics and Systems Medicine in Neurodegenerative Diseases, German Center for Neurodegenerative Diseases, Göttingen, Germany.
  • Berulava T; Department for Psychiatry and Psychotherapy, University Medical Center Göttingen, Göttingen, Germany.
  • Heilbronner U; Department for Epigenetics and Systems Medicine in Neurodegenerative Diseases, German Center for Neurodegenerative Diseases, Göttingen, Germany.
  • Budde M; Institute of Psychiatric Phenomics and Genomics (IPPG), University Hospital, Ludwig-Maximilians-University Munich, Munich, Germany.
  • Centeno TP; Institute of Psychiatric Phenomics and Genomics (IPPG), University Hospital, Ludwig-Maximilians-University Munich, Munich, Germany.
  • Elerdashvili V; Department for Epigenetics and Systems Medicine in Neurodegenerative Diseases, German Center for Neurodegenerative Diseases, Göttingen, Germany.
  • Zafieriou MP; Department for Epigenetics and Systems Medicine in Neurodegenerative Diseases, German Center for Neurodegenerative Diseases, Göttingen, Germany.
  • Benito E; Institute of Pharmacology and Toxicology, University Medical Center Göttingen, Göttingen, Germany.
  • Sertel SM; Department for Epigenetics and Systems Medicine in Neurodegenerative Diseases, German Center for Neurodegenerative Diseases, Göttingen, Germany.
  • Goldberg M; Department of Neuro- and Sensory Physiology, University Medical Center Göttingen, Göttingen, Germany.
  • Senner F; Department for Epigenetics and Systems Medicine in Neurodegenerative Diseases, German Center for Neurodegenerative Diseases, Göttingen, Germany.
  • Kalman JL; Institute of Psychiatric Phenomics and Genomics (IPPG), University Hospital, Ludwig-Maximilians-University Munich, Munich, Germany.
  • Burkhardt S; Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-University Munich, München, Germany.
  • Oepen AS; Institute of Psychiatric Phenomics and Genomics (IPPG), University Hospital, Ludwig-Maximilians-University Munich, Munich, Germany.
  • Sakib MS; Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-University Munich, München, Germany.
  • Kerimoglu C; Department for Epigenetics and Systems Medicine in Neurodegenerative Diseases, German Center for Neurodegenerative Diseases, Göttingen, Germany.
  • Wirths O; Department for Epigenetics and Systems Medicine in Neurodegenerative Diseases, German Center for Neurodegenerative Diseases, Göttingen, Germany.
  • Bickeböller H; Department for Epigenetics and Systems Medicine in Neurodegenerative Diseases, German Center for Neurodegenerative Diseases, Göttingen, Germany.
  • Bartels C; Department for Epigenetics and Systems Medicine in Neurodegenerative Diseases, German Center for Neurodegenerative Diseases, Göttingen, Germany.
  • Brosseron F; Department for Psychiatry and Psychotherapy, University Medical Center Göttingen, Göttingen, Germany.
  • Buerger K; Department of Genetic Epidemiology, University Medical Center Göttingen, Göttingen, Germany.
  • Cosma NC; Department for Psychiatry and Psychotherapy, University Medical Center Göttingen, Göttingen, Germany.
  • Fliessbach K; German Center for Neurodegenerative Diseases, Bonn, Germany.
  • Heneka MT; Department of Neurodegeneration and Geriatric Psychiatry, University Hospital Bonn, Bonn, Germany.
  • Janowitz D; German Center for Neurodegenerative Diseases (DZNE, Munich), Munich, Germany.
  • Kilimann I; Institute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, Munich, Germany.
  • Kleinedam L; Department of Psychiatry and Psychotherapy, Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Laske C; German Center for Neurodegenerative Diseases, Bonn, Germany.
  • Metzger CD; Department of Neurodegeneration and Geriatric Psychiatry, University Hospital Bonn, Bonn, Germany.
  • Munk MH; German Center for Neurodegenerative Diseases, Bonn, Germany.
  • Perneczky R; Department of Neurodegeneration and Geriatric Psychiatry, University Hospital Bonn, Bonn, Germany.
  • Peters O; Institute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, Munich, Germany.
  • Priller J; German Center for Neurodegenerative Diseases (DZNE), Rostock, Germany.
  • Rauchmann BS; Department of Psychosomatic Medicine, Rostock University Medical Center, Rostock, Germany.
  • Roy N; German Center for Neurodegenerative Diseases, Bonn, Germany.
  • Schneider A; Department of Neurodegeneration and Geriatric Psychiatry, University Hospital Bonn, Bonn, Germany.
  • Spottke A; Department of Psychosomatic Medicine, Rostock University Medical Center, Rostock, Germany.
  • Spruth EJ; Section for Dementia Research, Hertie Institute for Clinical Brain Research and Department of Psychiatry and Psychotherapy, University of Tübingen, Tübingen, Germany.
  • Teipel S; German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany.
  • Tscheuschler M; Institute of Cognitive Neurology and Dementia Research (IKND), Otto-von-Guericke University, Magdeburg, Germany.
  • Wagner M; Department of Psychiatry and Psychotherapy, Otto-von-Guericke University, Magdeburg, Germany.
  • Wiltfang J; Section for Dementia Research, Hertie Institute for Clinical Brain Research and Department of Psychiatry and Psychotherapy, University of Tübingen, Tübingen, Germany.
  • Düzel E; German Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany.
  • Jessen F; Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-University Munich, München, Germany.
  • Rizzoli SO; Munich Cluster for Systems Neurology (SyNergy) Munich, Munich, Germany.
  • Zimmermann WH; Ageing Epidemiology Research Unit (AGE), School of Public Health, Imperial College London, London, UK.
  • Schulze TG; Department of Psychiatry and Psychotherapy, Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Falkai P; German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany.
  • Sananbenesi F; German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany.
EMBO Mol Med ; 13(11): e13659, 2021 11 08.
Article em En | MEDLINE | ID: mdl-34633146
ABSTRACT
While some individuals age without pathological memory impairments, others develop age-associated cognitive diseases. Since changes in cognitive function develop slowly over time in these patients, they are often diagnosed at an advanced stage of molecular pathology, a time point when causative treatments fail. Thus, there is great need for the identification of inexpensive and minimal invasive approaches that could be used for screening with the aim to identify individuals at risk for cognitive decline that can then undergo further diagnostics and eventually stratified therapies. In this study, we use an integrative approach combining the analysis of human data and mechanistic studies in model systems to identify a circulating 3-microRNA signature that reflects key processes linked to neural homeostasis and inform about cognitive status. We furthermore provide evidence that expression changes in this signature represent multiple mechanisms deregulated in the aging and diseased brain and are a suitable target for RNA therapeutics.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: MicroRNAs / Doença de Alzheimer / Disfunção Cognitiva Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: MicroRNAs / Doença de Alzheimer / Disfunção Cognitiva Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article